Frutarom Health to Increase Phytopharmaceutical Capacity in Germany

01 Feb 2017 --- Frutarom Health BU has reported that it will strengthen focus on its phytopharmaceutical business in 2017. This follows the 2016 acquisition of Extrakt Chemie GmbH & Co and supports the rapid growth the company has planned for its pure phytopharmaceutical line.

The global size of the phytopharmaceutical market is estimated at €750-850 million, with 90% of the market concentrated domestically in the EU. German-speaking countries make up half of that market, followed by France.

The predominant health areas this market covers are: cough & cold; mental health (stress, mood, fatigue, restlessness, cognition); gastrointestinal disorders; and cardiovascular health.

Maider Gutierrez, Marketing Manager of Frutarom Health BU told NutritionInsight that the company is seeing an increasing demand for natural solutions to enhance cognitive performance.

"It is becoming extremely important to maintain an optimum cognitive function, especially in stressful situations which have become a normal part of our society," Gutierrez said. "More and more people perceive increasing levels of stress which, in the long run, could lead to health issues."

Frutarom Health plans to grow its Extrakt Chemie acquisition through globalization via Frutarom’s international sales network.

Frutarom say that it has initiated investments in the site to increase production capacity and fulfill the market needs of the pharmaceutical industry.

The company has implemented a third production shift, to be followed by an expansion of the site (including production and office areas) to establish Extrakt Chemie as Frutarom´s Pharma Competence Center.

“With the acquisition of Extrakt Chemie, plus the directed site investments in people, equipment, manufacturing buildings and new offices, and the new, combined team of highly experienced pharmaceutical experts, we feel Frutarom can bring significant value to the phytopharmaceuticals market,” says Barbara Bradl, Business Manager Pharma of Frutarom BU Health.

“Adding the legacy Extrakt Chemie portfolio to the already strong EFLApharm line of Frutarom Health product creates new market opportunities for all both the companies and consumers.”

“Growing this business is a key element of the Business Unit Health strategy.”

Frutarom’s premium portfolio of phytopharmaceutical ingredients, known as EFLApharm, has been significantly extended by such strategic acquisitions in the past 2 years.

All products under the umbrella of EFLApharm are pharma-grade herbal extracts, produced according to GMP guidelines, and offer an advanced market entity to our business partners.

The botanical extracts are suitable as APIs for the global pharmaceutical market, and are supported by a dedicated Regulatory Affairs team that provides specialized pharma services.

by Hannah Gardiner